Evidence map›Paper›PMID 28475816›Full record

Trial reportClinical cardiology2017

Interleukin-1 blockade in heart failure with preserved ejection fraction: rationale and design of the Diastolic Heart Failure Anakinra Response Trial 2 (D-HART2).

Benjamin W Van Tassell, Leo F Buckley, Salvatore Carbone, Cory R Trankle, Justin M Canada, Dave L Dixon, Nayef Abouzaki, Claudia Oddi-Erdle, Giuseppe Biondi-Zoccai, Ross Arena and 1 more

2 registry-linked trialsOpen access · bronzeAbstract readClinical Trial, Phase IIRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Clinical cardiology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 42 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed, 1 pooled it
6.2field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02173548 phase2completednot on this map

Interleukin-1 Blockade in Heart Failure With Preserved Ejection Fraction (HFpEF): a Randomized Placebo-controlled Double Blinded Study (D-HART2)

TypeinterventionalSponsorVirginia Commonwealth UniversityRan2014 to 2017Enrolled31ConditionsHeart Failure With Normal Ejection FractionArmsAnakinra, Placebo
NCT06130059 phase2recruitingnot on this mapstarted 2024, after this paper: background citation

Pilot Study to Evaluate the Efficacy of Low Dose Colchicine (LoDoCo ®) to Improve Exercise Capacity Among Patients With Chronic Stable HFpEF and Systemic Inflammation

TypeinterventionalSponsorUniversity of Texas Southwestern Medical CenterRan2024 to 2027Enrolled60ConditionsHeart Failure, InflammationArmsLow Dose Colchicine, Placebo
3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 1 synthesis or guideline pooled it, 69 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Review
  6. An integrated overview of acute heart failure: a narrative review of pathophysiological mechanisms and contributing factors.The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology · 2026
    Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. Inflammation in Heart Failure-Future Perspectives.Journal of clinical medicine · 2023
    Review
  16. Chalcone: A potential scaffold for NLRP3 inflammasome inhibitors.European journal of medicinal chemistry reports · 2023
    Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Benjamin W Van TassellDepartment of Pharmacotherapy and Outcomes Science, Virginia Commonwealth University, Richmond.
Leo F BuckleyDepartment of Pharmacotherapy and Outcomes Science, Virginia Commonwealth University, Richmond.ORCID http://orcid.org/0000-0003-1570-1486
Salvatore CarboneVCU Johnson Center for Pulmonary and Critical Care Research, Virginia Commonwealth University, Richmond.
Cory R TrankleVCU Johnson Center for Pulmonary and Critical Care Research, Virginia Commonwealth University, Richmond.
Justin M CanadaVCU Johnson Center for Pulmonary and Critical Care Research, Virginia Commonwealth University, Richmond.
Dave L DixonDepartment of Pharmacotherapy and Outcomes Science, Virginia Commonwealth University, Richmond.
Nayef AbouzakiVCU Johnson Center for Pulmonary and Critical Care Research, Virginia Commonwealth University, Richmond.
Claudia Oddi-ErdleVCU Johnson Center for Pulmonary and Critical Care Research, Virginia Commonwealth University, Richmond.
Giuseppe Biondi-ZoccaiDepartment of Medical and Surgical Sciences and Biotechnologies, Sapienza University of Rome, Latina, and Department of AngioCardioNeurology, IRCCS Neuromed, Pozzilli, Italy.
Ross ArenaDepartment of Physical Therapy, College of Applied Health Sciences, University of Illinois at Chicago.
Antonio AbbateVCU Johnson Center for Pulmonary and Critical Care Research, Virginia Commonwealth University, Richmond.
Virginia Commonwealth University · USIstituto Neurologico Mediterraneo · ITUniversity of Illinois Chicago · US

Funding

Center for Clinical and Translational ResearchUL1TR000058 · NCATS · VIRGINIA COMMONWEALTH UNIVERSITY · PI MOELLER, FREDERICK GERARD · 2012 to 2015
$12.5M
Interleukin-1 blockade in heart failure with preserved ejection fractionR34HL118348 · NHLBI · VIRGINIA COMMONWEALTH UNIVERSITY · PI ABBATE, ANTONIO, VAN TASSELL, BENJAMIN W · 2014 to 2015
$681k
NCATS NIH HHS UL1 TR000058NHLBI NIH HHS R34 HL118348
6 · The paper itself

Abstract

Heart failure with preserved ejection fraction (HFpEF) now accounts for the majority of confirmed HF cases in the United States. However, there are no highly effective evidence-based treatments currently available for these patients. Inflammation correlates positively with adverse outcomes in HF patients. Interleukin (IL)-1, a prototypical inflammatory cytokine, has been implicated as a driver of diastolic dysfunction in preclinical animal models and a pilot clinical trial. The Diastolic Heart Failure Anakinra Response Trial 2 (D-HART2) is a phase 2, 2:1 randomized, double-blind, placebo-controlled clinical trial that will test the hypothesis that IL-1 blockade with anakinra (recombinant human IL-1 receptor antagonist) improves (1) cardiorespiratory fitness, (2) objective evidence of diastolic dysfunction, and (3) elevated inflammation in patients with HFpEF (http://www.ClinicalTrials.gov NCT02173548). The co-primary endpoints will be placebo-corrected interval changes in peak oxygen consumption and ventilatory efficiency at week 12. In addition, secondary and exploratory analyses will investigate the effects of IL-1 blockade on cardiac structure and function, systemic inflammation, endothelial function, quality of life, body composition, nutritional status, and clinical outcomes. The D-HART2 clinical trial will add to the growing body of evidence on the role of inflammation in cardiovascular disease, specifically focusing on patients with HFpEF.

Indexed as

Ventricular Function, LeftAnti-Inflammatory AgentsCardiorespiratory FitnessCardiovascular AgentsClinical ProtocolsCross-Over StudiesDouble-Blind MethodExercise ToleranceHeart FailureHeart VentriclesHumansInterleukin-1Interleukin 1 Receptor Antagonist ProteinPilot ProjectsRecovery of FunctionResearch DesignAnti-Inflammatory AgentsCardiovascular AgentsInterleukin-1Interleukin 1 Receptor Antagonist Proteinclinical trial study designHeart FailureInterleukin-1

Identifiers

PMID28475816
PMCPMC5744484
OpenAlexW2610719842

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.